Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02530463

Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The goal of this clinical research study is to learn if nivolumab and/or ipilimumab, with or without azacitidine, are safe to give to patients with MDS. Researchers also want to learn if the study drug combinations can help to control the disease.

Status: 
Recruiting
Study Date: 
Tue, 09/01/2015 to Wed, 09/01/2021
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Nivolumab 3 mg/kg by vein every 2 weeks. Other Names: BMS-936558 Opdivo Drug: Ipilimumab 3 mg/kg by vein every 3 weeks. Other Names: Yervoy BMS-734016 MDX010 Drug: 5-azacitidine 75 mg/m2 by vein for 5 days every 4 weeks. Other Names: Azacitidine 5-aza Vidaza 5-AZC AZA-CR Ladakamycin NSC-102816 Azacytidine